Healthcare News / Premier Biomedical, Inc

PBI Signs Contract with UTEP for Cancer Treatment Methodology Protocol Shown to Greatly Increase Survival and Prevention of Breast Cancer Metastasis

Via: ReleaseWire

Updated 9:45 AM CDT, Thu, April 16,2015

El Paso, TX -- (ReleaseWire) -- 04/16/2015 -- Premier Biomedical Inc. (OTCQB: BIEI) signed a Patent License Agreement with the University of Texas El Paso (UTEP), covering the cancer treatment process called "CD152-LDMC" which the two entities have been developing in cooperation at the prestigious Border Biomedical Research Center, housed in UTEP's $45-million Bioscience Research Building.

More than 80 faculty members from departments including chemistry, psychology, sociology and biological, geological and mathematical sciences conduct research in the center's labs.

The proprietary process seeks to block a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4, by combining CTLA-4 blocking antibody CD152, along with Low Dose Metronomic Chemotherapy.

Significant progress has been made over the past year advancing the development of CD152-LDMC.

CTLA-4 is believed to play a role in slowing down or turning off the body's immune system, affecting its ability to fight off cancerous cells. CD152-LDMC's goal is to block CTLA-4, allowing the body's immune system to recognize, target, and attack cells in cancerous tumors. The CD152 antibody is similar to the Ipilimumab anti-CTLA-4 antibody (Bristol-Meyers-Squibb's Yervoy®) used for treatment of metastatic melanoma. Ipilimumab and pembrolizumab (Merck's Keytruda®) are the only two cancer immunotherapeutic drugs approved by the FDA to date, both of which are used in the treatment of melanoma.

Dr. Giulio Francia, Assistant Professor at UTEP, said, "We are excited about these preclinical breast cancer studies and on the impact that low dose chemotherapy strategies can have in contributing to the disruption of tumor growth. Ultimately, once approved, such therapies should produce fewer treatment side effects without limiting the clinical effectiveness of the drugs."

Researchers at UTEP have previously presented positive results from duplicated testing of CD152-LDMC on mice at the American Association for Cancer Research annual meeting in San Diego last April. These results showed statistically significant improvements in survival and prevention of breast cancer in mice treated with the CD152-LDMC anti-breast cancer treatment versus chemotherapy-only, and non-treated groups. Most significantly, UTEP has also shown the prevention of breast cancer metastasis in mice.

William A. Hartman, President and CEO of Premier, stated, "This agreement is just the latest step in our positive, on-going working relationship with this outstanding research institute. Dr. Francia and his staff, are world-class researchers, and we are fortunate to be working with them. We look forward to many more such mutually beneficial technological developments."

The process is one of two being jointly studied at UTEP. In addition to CD-152-LDMC, the University is making significant progress with a Sequential-Dialysis machine called the Felder Pathogen Filter (FPF). The company's goal is for the FPF to directly remove metastatic cancer cells, tau proteins, and other harmful substances from the blood for blood-borne diseases and ultimately physically remove the underlying causes of the diseases.

Premier Biomedical is continuing their research at UTEP, as the company believes that this represents a major step in the goal of preventing breast cancer metastasis and defeating cancer in a completely nontoxic manner by utilizing the body's own immune system. Premier has released the photographic results here.

Direct phone inquiries to Premier Biomedical at PBI-MED-7033 (724-633-7033)

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Source: UPTICK Newswire

For more information on this press release visit:

Media Relations Contact
Everett Jolly
Email: Click to Email Everett Jolly